- Breaking News San Mateo County ninth-graders struggle to stay fit
- Breaking News Food and wine events
- Breaking News Ask Amy: What To Do When the Doctor Isn t in the House
- Breaking News Ed Blonz: Keep your diet normal pre-surgery
Drug doubles survival rate among kidney cancer patients: study
0 Comments | AFP, June, 2007
CHICAGO (AFP) — Anticancer drug Avastin, used for treating lung and colon cancer, has led to the doubling of the survival rate of people affected by kidney cancer, according to a new study released Saturday.
The study, which surveyed 649 patients worldwide, showed that those who received Avastin, also known as bevacizumab, had a median survival rate of 10.2 months compared to 5.4 months for others.
Avastin is marketed in the United States by Genentech, a leading biotechnology company, and by Swiss firm Roche in Europe. The two companies sponsored the survey.
The study was unveiled late Saturday at the 43rd annual meeting of the American Society of Clinical Oncology.
"We're in a very exciting time in kidney cancer research, with a number of new...
- Getting to the root of beautiful hair: shiny, silky hair begins with a healthy scalp - includes list of resources and a recipe for an herbal scalp tonic
- Portfolio forecasting tools: what you need to know
- Made from scratch: When Honda built a plant in Alabama it also built a workforce-using local workers who had no experience in making cars - Recruitment & Hiring
- Industry Experts Launch Money Management Resources to Help People Overcome Debt and Learn Proper Money Management Practices
- Funds transfer pricing: A perspective on policies and operations
- Taylor Fund L.P. Gains 40.53% in Third Quarter
- A multi-class SVM classifier utilizing binary decision tree
- Why fly solo when an executive assistant can accelerate your CLNC® business?